0 Recommendations

2 important publications on newer TB drugs

By Erica Lessem | 07 Sep, 2017

Dear all,

Please see below two important recent publications on the use of bedaquiline and delamanid (full disclosure-- I am co-author on first piece)

The first describes how to choose between bedaquiline and delamanid for an individual patient, and notes, "tuberculosis programmes should make both bedaquiline and delamanid available. Although there are no efficacy data to guide the choice of one agent over the other, there are clinical scenarios that favour either bedaquiline or delamanid, and there are some patients who will need both."
Full article attached; the link is here: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2817%2930309-0...

The second summarizes data on the use of bedaquiline in adolescents and children in MSF programs, noting, "Our experience suggests that bedaquiline can be used safely in children >12 years of age with appropriate monitoring and could be considered in younger children in select circumstances when benefits are likely to outweigh risks."
https://wwwnc.cdc.gov/eid/article/23/10/17-0303_article

I hope this can stimulate use of the drugs in your setting. Are you able to access both bedaquiline and delamanid? Do you have patients who may require off-label use, such as patients who need both drugs due to extensive resistance, or adolescents?
 
Best,
Erica

Erica Lessem, MPH
Director, TB/HIV Project
Treatment Action Group
90 Broad St, Suite 2503
New York, NY 10004 USA
tel: +1.212.253.7922
mobile: +1.617.827.2461
www.treatmentactiongroup.org

Replies

 

Elijah Amooti Replied at 3:15 AM, 8 Sep 2017

Hello Erica,
Thanks for the article it was well written and educative ,to answer your question Do you have patients who may require off-label use, such as patients who need both drugs due to extensive resistance? my answer is that European African treatment Advocates Network /EATAN international relations Lead Mr Moses Waswa works closely with medical practitioners in Europe and Africa I will put you in contact .

Kind regards
Elijah Amooti

Chair

European African Treatment Advocates Network (EATAN)

Belgium Office

Rue Abbé Cuypers 3
1040 Brussel

UK office:

76 Elmer Road, London SE6 2ER

Tel: +4420 8698 6920

Mob:+447475446182

Email:

Web: www.eatan.eu

EATAC CIC No:09734939

EATAN :Empowering Patients, Improving Health Options

This Community is Archived.

This community is no longer active as of December 2018. Thanks to those who posted here and made this information available to others visiting the site.